文献速递腹部技术与安全MR

预测巨梁状-块状亚型肝细胞癌的MRI影像特征:系统综述与Meta分析

MRI imaging features for predicting macrotrabecular-massive subtype hepatocellular carcinoma: a systematic review and meta-analysis.
PubMed 文献 · Eur Radiol · 2024-03-20

该系统综述与Meta分析纳入10项研究共1978例患者2031个肝细胞癌病灶,评估与巨梁状-块状亚型肝细胞癌(MTM-HCC)相关的MRI特征及LI-RADS分类分布。结果显示肿瘤侵犯静脉、环状动脉期高强化、晕环强化、瘤内动脉、肝胆期瘤周低信号和坏死6个MRI特征与MTM-HCC显著相关,且MTM-HCC较非MTM-HCC更易归为LR-M和LR-TIV、更少归为LR-5。

要点

  • 坏死与MTM-HCC关联最强(DOR=4.2,95%CI 2.0-8.5),其次为肿瘤侵犯静脉、环状动脉期高强化、晕环强化和瘤内动脉(DOR均为2.6)。
  • MTM-HCC的LI-RADS分类中LR-5占63%、LR-M占12%、LR-TIV占13%,LR-M和LR-TIV比例高于非MTM-HCC。
  • 识别上述MRI特征可提示MTM-HCC亚型,有助于指导治疗决策和筛选新治疗策略临床试验的潜在候选者。

核心结论

  • 6个MRI特征与MTM-HCC显著相关;相比非MTM-HCC,MTM-HCC更可能被归类为LR-M和LR-TIV,更少被归类为LR-5。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed和EMBASE至2023年3月28日,纳入10项研究共1978例患者2031个肝细胞癌病灶(MTM-HCC 426个,占20.9%;非MTM-HCC 1605个,占79.1%),采用随机效应模型计算合并诊断比值比(DOR)及95%CI。

诊断标准与关键数值

  • 肿瘤侵犯静脉DOR=2.4(95%CI 1.6-3.5);环状动脉期高强化DOR=2.6(95%CI 1.4-5.0);晕环强化DOR=2.6(95%CI 1.4-4.5);瘤内动脉DOR=2.6(95%CI 1.1-6.3);肝胆期瘤周低信号DOR=2.2(95%CI 1.5-3.3);坏死DOR=4.2(95%CI 2.0-8.5)。MTM-HCC的LI-RADS分类合并比例:LR-3为0%(95%CI 0-2%)、LR-4为11%(95%CI 6-16%)、LR-5为63%(95%CI 55-71%)、LR-M为12%(95%CI 6-19%)、LR-TIV为13%(95%CI 6-22%);非MTM-HCC:LR-3为1%(95%CI 0-2%)、LR-4为8%(95%CI 3-15%)、LR-5为77%(95%CI 71-82%)、LR-M为5%(95%CI 3-7%)、LR-TIV为6%(95%CI 2-11%)。

临床应用与阅片要点

  • 阅片时可关注肿瘤侵犯静脉、环状动脉期高强化、晕环强化、瘤内动脉、肝胆期瘤周低信号和坏死等MRI特征,这些特征可提示MTM-HCC亚型,有助于指导治疗计划和识别新治疗策略临床试验的潜在候选者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To identify significant MRI features associated with macrotrabecular-massive hepatocellular carcinoma (MTM-HCC), and to assess the distribution of Liver Imaging Radiology and Data System (LI-RADS, LR) category assignments.

METHODS: PubMed and EMBASE were searched up to March 28, 2023. Random-effects model was constructed to calculate pooled diagnostic odds ratios (DORs) and 95% confidence intervals (CIs) for each MRI feature for differentiating MTM-HCC from NMTM-HCC. The pooled proportions of LI-RADS category assignments in MTM-HCC and NMTM-HCC were compared using z-test.

RESULTS: Ten studies included 1978 patients with 2031 HCCs (426 (20.9%) MTM-HCC and 1605 (79.1%) NMTM-HCC). Six MRI features showed significant association with MTM-HCC: tumor in vein (TIV) (DOR = 2.4 [95% CI, 1.6-3.5]), rim arterial phase hyperenhancement (DOR =2.6 [95% CI, 1.4-5.0]), corona enhancement (DOR = 2.6 [95% CI, 1.4-4.5]), intratumoral arteries (DOR = 2.6 [95% CI, 1.1-6.3]), peritumoral hypointensity on hepatobiliary phase (DOR = 2.2 [95% CI, 1.5-3.3]), and necrosis (DOR = 4.2 [95% CI, 2.0-8.5]). The pooled proportions of LI-RADS categories in MTM-HCC were LR-3, 0% [95% CI, 0-2%]; LR-4, 11% [95% CI, 6-16%]; LR-5, 63% [95% CI, 55-71%]; LR-M, 12% [95% CI, 6-19%]; and LR-TIV, 13% [95% CI, 6-22%]. In NMTM-HCC, the pooled proportions of LI-RADS categories were LR-3, 1% [95% CI, 0-2%]; LR-4, 8% [95% CI, 3-15%]; LR-5, 77% [95% CI, 71-82%]; LR-M, 5% [95% CI, 3-7%]; and LR-TIV, 6% [95% CI, 2-11%]. MTM-HCC had significantly lower proportion of LR-5 and higher proportion of LR-M and LR-TIV categories.

CONCLUSIONS: Six MRI features showed significant association with MTM-HCC. Additionally, compared to NMTM-HCC, MTM-HCC are more likely to be categorized LR-M and LR-TIV and less likely to be categorized LR-5.

CLINICAL RELEVANCE STATEMENT: Several MR imaging features can suggest macrotrabecular-massive hepatocellular carcinoma subtype, which can assist in guiding treatment plans and identifying potential candidates for clinical trials of new treatment strategies.

KEY POINTS: • Macrotrabecular-massive hepatocellular carcinoma is a subtype of HCC characterized by its aggressive nature and unfavorable prognosis. • Tumor in vein, rim arterial phase hyperenhancement, corona enhancement, intratumoral arteries, peritumoral hypointensity on hepatobiliary phase, and necrosis on MRI are indicative of macrotrabecular-massive hepatocellular carcinoma. • Various MRI characteristics can be utilized for the diagnosis of the macrotrabecular-massive hepatocellular carcinoma subtype. This can prove beneficial in guiding treatment decisions and identifying potential candidates for clinical trials involving novel treatment approaches.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Kim TH, Woo S, Lee DH, et al. MRI imaging features for predicting macrotrabecular-massive subtype hepatocellular carcinoma: a systematic review and meta-analysis. Eur Radiol. 2024. PMID: 38507054. doi:10.1007/s00330-024-10671-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。